Lead(II) acetate is a white crystalline chemical compound with a sweetish taste. Lead(II) acetate is used as a mordant in textile printing and dyeing, as a drier in paints and varnishes, and in preparing other lead compounds. It was historically used as a sweetener and for cosmetics.

Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.

Rubidium chloride is an inorganic compound with the formula RbCl. It appears to be nontoxic and therapeutically effective in several types of depressive disorders. This drug develops his action on dopaminergic stimulation reducing the depressive pattern. Also radioactive rubidium-82 chloride is used as diagnostic agent in positron emission tomography (PET).

Zuretinol (QLT091001, 9-cis-retinol) is a retinoid. Retinoids (vitamin A and its analogs) are essential dietary substances that are needed by mammals for reproduction, normal embryogenesis, growth, vision, and maintaining normal cellular differentiation and the integrity of the immune system. Within cells, retinoids regulate gene transcription acting through ligand-dependent transcription factors, the retinoic acid receptors (RARs), and the retinoid X receptors (RXRs). All-trans-retinoic acid binds only to RARs with high affinity, whereas its 9-cis isomer binds with high affinity to both RARs and RXRs. The actions of all-trans- and 9-cis-retinoic acid in regulating cellular responses are distinct and not interchangeable. Zuretinol is a retinal derivative for treatment of visual disorders. It is a synthetic retinoid replacement for 11-cis-retinal. It is an investigational product under development for the treatment of retinal diseases caused by gene mutations that interfere with the availability of 11-cis-retinal. The therapeutic strategy with Zuretinol is to facilitate recovery or restoration of visual function by acting as a replacement for missing 11-cis-retinal and restoring a key biochemical component of the visual (retinoid) cycle. Novelion Therapeutics is currently developing QLT091001 for the treatment of Inherited Retinal Disease caused by retinal pigment epithelium protein 65 (“RPE65”) and lecithin:retinol acyltransferase (“LRAT”) gene mutations, which include Leber Congenital Amaurosis (“LCA”) and Retinitis Pigmentosa (“RP”). QLT091001 has received orphan drug designations for the treatment of LCA (due to inherited mutations in the LRAT and RPE65 genes) and RP (all mutations) by the U.S. Food and Drug Administration (the “FDA”), and for the treatment of LCA and RP (all mutations) by the European Medicines Agency (the “EMA”).

Sodium acetate C-11 (C-11 acetate) Injection is a radiopharmaceutical commonly used for clinical studies with positron emission tomography (PET). It is used as a PET radiotracer for imaging cancer cells via incorporation into intracellular phosphatidylcholine membrane microdomains in cancer cells. Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. C-11 acetate is taken up in proportion to fatty acid synthesis. It is also taken up proportionally to myocardial blood flow, and therefore myocardial oxygen consumption. In rodents, there is clearance from all organs except the pancreas within one hour. Tumor uptake was clearly visible in 30 minutes. In humans, more than 80% of tracer is cleared from normal tissues within 20 minutes.It is taken up in cancer within the prostate and prostate cancer metastases, however, it has been reported that increased uptake can be seen in hyperplastic and benign prostate tissues. No urinary excretion is seen. No toxic effects have been demonstrated. The ongoing clinical trial NCT01530269 is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments of prostate cancer.